LAIYANG, China, June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it will attend the China New Drugs Trade Fair from June 26 to 28, 2009 at Tianjin Binhai International Convention & Exhibition Center, and also plans to launch a new promotional campaign for its recently acquired Laiyang Pear Cough Syrup.
Jiangbo plans to promote its brand at the trade fair to increase the popularity of its Traditional Chinese Medicine (TCM) products. The Company will promote the portfolio of TCM products it acquired by purchasing Hongrui Pharmaceutical Company in early 2009 to its existing customers, and speak with new potential distributors.
Laiyang City is famous for its pears. "Laiyang Pear" is a trademark for place of origin which is registered with the Chinese National Industrial and Commercial Bureau. In production by Jiangbo since April of 2009, Laiyang Pear Cough Syrup is made from Laiyang Pears and is used to relieve coughs and remove phlegm arising from colds or other ailments. The Company believes that Laiyang Pear Cough Syrup tastes much better than alternative cough syrups. The cough syrup's pear taste makes it especially popular among children.
As a leading manufacturer using Laiyang Pears in a cough syrup, Jiangbo intends to leverage its location in Laiyang and extensive sales network to become the market leader for this type of cough syrup.
"We look forward to attending the trade fair. We plan to renew old contacts, and hope to develop new relationships with distributors through which we will increase our TCM sales," said Mr. Wubo Cao, CEO of Jiangbo. "Separately, we plan to start an active promotional campaign for our Laiyang Pear Cough Syrup. The current market size for cough syrups in China is approximately RMB 5 to 10 billion annually and is rapidly growing. We currently estimate that our sales of Laiyang Pear Cough Syrup in China will reach RMB 500 million within the next five years."
About the 44th China New Drugs Trade Fair
The China New Drugs Trade Fair is a professional forum for individuals and companies interested in commercializing drugs and new pharmaceutical products in China. The event will be held June 26 to 28 at the Binhai International Convention & Exhibition Center in Tianjin, China. The trade fair plays an important role in connecting "Government, industry, academic research, funding and service." More than 70,000 professionals are expected to attend the trade fair. For more information about the China New Drugs Trade Fair, please visit http://en.newdrugschina.com .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-727-8435 Email: email@example.com http://www.jiangbopharma.com CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: firstname.lastname@example.org http://www.ccgirasia.com
|SOURCE Jiangbo Pharmaceuticals Enterprises, Inc.|
Copyright©2009 PR Newswire.
All rights reserved